{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SL+placebo+tablets", "query": { "intervention": "SL placebo tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SL+placebo+tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T19:05:04.454Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02651584", "title": "Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Opioid Use Disorders" ], "interventions": [ { "name": "CAM2038 SC injection", "type": "DRUG" }, { "name": "SL BPN/NX tabs", "type": "DRUG" }, { "name": "placebo SC injections", "type": "DRUG" }, { "name": "SL placebo tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Braeburn Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 428, "start_date": "2015-12", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2019-08-22", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" }, { "city": "Hamilton", "state": "Alabama" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02651584" }, { "nct_id": "NCT04508621", "title": "A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibromyalgia" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo SL Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 514, "start_date": "2020-07-22", "completion_date": "2021-11-01", "has_results": true, "last_update_posted_date": "2023-12-18", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508621" }, { "nct_id": "NCT01677182", "title": "Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Ramelteon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 535, "start_date": "2012-08", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-03-16", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Anaheim, California • Glendale, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Imperial", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677182" }, { "nct_id": "NCT07621237", "title": "A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Episode (MDE)", "Major Depressive Disorder (MDD)", "Depression" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo sublingual tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 360, "start_date": "2026-06", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Chino, California • Lemon Grove, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chino", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07621237" }, { "nct_id": "NCT01903265", "title": "BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Primary Fibromyalgia" ], "interventions": [ { "name": "TNX-102 SL 2.8mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 205, "start_date": "2013-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-12-23", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 17, "location_summary": "Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Brooksville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01903265" }, { "nct_id": "NCT05472090", "title": "A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection", "COVID-19", "Long COVID", "Long Haul COVID" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo SL Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 63, "start_date": "2022-08-18", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Oceanside, California • Santa Ana, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oceanside", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05472090" }, { "nct_id": "NCT01467713", "title": "Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Ramelteon SL", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 642, "start_date": "2011-12", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-05-16", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 138, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 134 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467713" }, { "nct_id": "NCT05273749", "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibromyalgia" ], "interventions": [ { "name": "TNX-102 SL Tablet, 5.6 mg", "type": "DRUG" }, { "name": "Placebo SL Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 457, "start_date": "2022-04-06", "completion_date": "2023-11-14", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Oceanside, California • Santa Ana, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Cromwell", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05273749" }, { "nct_id": "NCT03841773", "title": "A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" }, { "name": "Placebo SL Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 192, "start_date": "2019-03-07", "completion_date": "2020-04-24", "has_results": true, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841773" }, { "nct_id": "NCT01395992", "title": "Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar I Disorder" ], "interventions": [ { "name": "asenapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2012-04", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-05-27", "last_synced_at": "2026-09-13T19:05:04.454Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01395992" } ] }